Strategic partnerships DCRI is expanding collaborations with industry leaders and foundations, evidenced by recent partnerships with Amgen Foundation and IQVIA to enhance data reevaluation, obesity and cardiometabolic trials, and cardiovascular prevention therapies—opportunities to position DCRI for sponsored research, data analytics, and joint trial programs.

Cardiovascular focus With formal three-year partnerships to advance cardiovascular prevention therapies and a strong presence at major cardiovascular events, there is a clear market runway for DCRI to offer specialized trial design, regulatory strategy, and real-world evidence generation in cardiology.

Academic CRO strengths As an academic clinical research organization embedded in Duke University, DCRI combines physician expertise with full-service CRO capabilities across Phase I to IV, enabling high-quality trials, post-approval analyses, and health economics studies that appeal to sponsors seeking rigorous academic-academic-industry collaboration.

Impressive scale and impact Large-scale operations (over 1,000 employees, revenue in the hundreds of millions) and a prolific publication footprint position DCRI as a credible partner for large, multinational trials and data-intensive programs, appealing to sponsors requiring robust oversight and scientific credibility.

Regulatory and clinical pathways Recent announcements about establishing regulatory pathways for cardiovascular therapies and ongoing engagement with key scientific communities (AHA sessions, CVCT) indicate opportunities to offer strategic regulatory consulting, trial governance, and outcomes research to align with FDA expectations and payer needs.